METHOD AND COMPOSITION FOR TREATING CYSTIC FIBROSIS
    13.
    发明申请
    METHOD AND COMPOSITION FOR TREATING CYSTIC FIBROSIS 审中-公开
    用于治疗CYSTIC FIBROSIS的方法和组合

    公开(公告)号:WO1996006612A1

    公开(公告)日:1996-03-07

    申请号:PCT/US1995011008

    申请日:1995-08-29

    Abstract: A method and composition for treating cystic fibrosis comprising administering to a patient a first component, a second component, and preferably a third component. The first component is an inhibitor which is specific for a cGMP-inhibited type III cAMP phosphodiesterase, preferably milrinone or amrinone; the second component is an adenylate cyclase activator, preferably forskolin, isoproterenol or albuterol; the third component is cAMP or cAMP analog which activates protein kinase A.

    Abstract translation: 一种用于治疗囊性纤维化的方法和组合物,包括向患者施用第一组分,第二组分,优选第三组分。 第一组分是对于cGMP抑制型IIIcAMP磷酸二酯酶,优选米力农或氨力农特异的抑制剂; 第二组分是腺苷酸环化酶活化剂,优选福斯克林,异丙肾上腺素或沙丁胺醇; 第三种成分是激活蛋白激酶A的cAMP或cAMP类似物。

    PHTHALOCYANINE PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY AND METHODS FOR THEIR SYNTHESIS AND USE
    14.
    发明申请
    PHTHALOCYANINE PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY AND METHODS FOR THEIR SYNTHESIS AND USE 审中-公开
    光化学治疗用的光化学光敏剂及其合成与使用方法

    公开(公告)号:WO1995006688A1

    公开(公告)日:1995-03-09

    申请号:PCT/US1994010052

    申请日:1994-08-31

    Abstract: The present invention relates to a series of novel phthalocyanine compositions (or compounds) suitable for use as photosensitizers for photodynamic therapy. Specifically, the invention relates to a series of new aluminum (Al) and/or silicon (Si) phthalocyanines having substituted amine or quaternary ammonium axial ligands attached to the central metal, and the use of these new phthalocyanine compositions for the treatment of cancer through photosensitization. Moreover, the present invention is directed to the methods of preparing these compositions for use in photodynamic therapy.

    Abstract translation: 本发明涉及一系列适用于光动力疗法的光敏剂的新型酞菁组合物(或化合物)。 具体地,本发明涉及一系列具有连接到中心金属的取代的胺或季铵轴配体的新的铝(Al)和/或硅(Si)酞菁,以及这些新的酞菁组合物用于治疗癌症的用途 光敏。 此外,本发明涉及制备用于光动力疗法的这些组合物的方法。

    GROWTH OF DIAMOND CRYSTALS
    16.
    发明申请
    GROWTH OF DIAMOND CRYSTALS 审中-公开
    钻石水晶的生长

    公开(公告)号:WO1993022482A1

    公开(公告)日:1993-11-11

    申请号:PCT/US1993004477

    申请日:1993-05-04

    CPC classification number: C23C16/458 C23C16/0272 C23C16/27 C30B25/02 C30B29/04

    Abstract: The present invention relates to a method of depositing diamond crystals using apparatus of the type conventionally employed in subatmospheric pressure deposition apparatus wherein improved deposition is achieved by employing a substrate such as graphite, related aromatic ring compounds, beryllium oxide, hexagonal boron nitride, molybdenum, silicon, diamond or the like, as well as effecting an increase in the rate of mass transfer, such as by imparting motion to the substrate during deposition.

    Abstract translation: 本发明涉及使用通常用于低于大气压力沉积设备的设备沉积金刚石晶体的方法,其中通过使用诸如石墨,相关芳环化合物,氧化铍,六方氮化硼,钼, 硅,金刚石等,以及实现质量传递速率的增加,例如通过在沉积期间赋予衬底运动。

    MICTURITIONAL ASSIST DEVICE
    17.
    发明申请
    MICTURITIONAL ASSIST DEVICE 审中-公开
    MICTURITIONAL ASSIST设备

    公开(公告)号:WO1992015366A1

    公开(公告)日:1992-09-17

    申请号:PCT/US1992001951

    申请日:1992-03-10

    CPC classification number: A61N1/36007 A61N1/0556

    Abstract: Cuff electrodes (40a, 40b) are surgically implanted around S3 sacral ventral root nerve trunks (16a, 16b). The sacral ventral roots have smaller diameter nerve fibers (20a, 20b) which convey action potentials to cause detrusor activation to contract the bladder (10) and larger diameter nerve fibers (18a, 18b) which carry action potentials for causing contraction of a urethral sphincter (12) to block the flow of urine from the bladder. A current source (50) causes current pulses (52) between such electrical contacts (46, 48) and a central electrical contact (44). The current pulses have an appropriate amplitude and waveform to initiate action potentials adjacent the central contact and to block the propagation of action potential adjacent the end electrodes along the larger diameter nerve fibers (which have fewer nodes between the contacts) but not the smaller diameter nerve fibers (which have more nodes between the electrodes). In this manner, action potentials are electrically excited to propagate at least downstream on the smaller diameter nerve fibers causing contraction of the bladder. Concurrently, blocking action potentials are allowed to propagate upstream on at least the larger diameter nerve fibers, collision blocking naturally occurring action potentials propagating downstream. The transmission of action potentials downstream on the larger diameter nerve fibers is blocked by the current pulses allowing the urinary sphincter to relax.

    DIAGNOSTIC AND PROGNOSTIC METHODS BASED ON SOLUBLE DERIVATIVES OF THE BETA AMYLOID PROTEIN PRECURSOR
    18.
    发明申请
    DIAGNOSTIC AND PROGNOSTIC METHODS BASED ON SOLUBLE DERIVATIVES OF THE BETA AMYLOID PROTEIN PRECURSOR 审中-公开
    基于β-淀粉样蛋白前体的可溶性衍生物的诊断和预防方法

    公开(公告)号:WO1992000521A1

    公开(公告)日:1992-01-09

    申请号:PCT/US1991004607

    申请日:1991-06-27

    CPC classification number: C07K14/4711 G01N33/6896 G01N2800/2821

    Abstract: The present invention relates to methods for the prognosis, diagnosis, and staging of Alzheimer's Disease (AD), and to methods for monitoring response to therapy in a patient with AD. The methods of the invention involve the measurement of the levels in a sample of cerebrospinal fluid (CSF) of the SIMILAR 25 kDa, SIMILAR 105 kDa, and SIMILAR 125 kDa soluble derivatives of the beta amyloid protein precursor ( beta APP). In specific embodiments, detection of an increase in the percentage amount of the SIMILAR 25 kDa protein and/or decrease in the percentage amount of the SIMILAR 105 kDa derivative and/or high absolute levels of all three soluble beta APP derivatives, relative to healthy individuals, can be used to diagnose or prognose AD. The foregoing can also be used to diagnose Down's syndrome, to prognose disorders in Down's syndrome patients associated with amyloid deposition, and as an indication of neurologic aging. In other embodiments, determination of the percentage amounts of the SIMILAR 25 kDa protein and/or the SIMILAR 105 kDa protein relative to such amount present prior to therapy or in healthy individuals can be deemed a poor response to therapy of AD. The invention is also directed to the soluble SIMILAR 25 kDa amino-terminal form of the beta APP.

    Abstract translation: 本发明涉及阿尔茨海默病(AD)的预后,诊断和分期方法,以及用于监测AD患者治疗反应的方法。 本发明的方法涉及测量β淀粉样蛋白前体(βAPP)的类似25kDa,类似105kDa和类似125kDa可溶性衍生物的脑脊髓液(CSF)样品中的水平。 在具体实施方案中,相对于健康个体,检测到类似的25kDa蛋白的百分数的增加和/或SIMILAR 105kDa衍生物的百分比的量的减少和/或所有三种可溶性βAPP衍生物的高绝对水平 ,可用于诊断或预后AD。 上述内容也可用于诊断唐氏综合征,预测唐氏综合征患者与淀粉样蛋白沉积相关的疾病,并作为神经衰老的指征。 在其它实施方案中,相对于在治疗前或健康个体中存在的量的相似25kDa蛋白和/或SIMILAR 105kDa蛋白的百分比量的确定可被认为对AD治疗的反应差。 本发明还涉及βAPP的可溶性类似的25kDa氨基末端形式。

    CRYOPRESERVATION AND EXTENSIVE SUBCULTURING OF HUMAN MESENCHYMAL STEM CELLS
    19.
    发明申请
    CRYOPRESERVATION AND EXTENSIVE SUBCULTURING OF HUMAN MESENCHYMAL STEM CELLS 审中-公开
    人间神经干细胞的CRYOPRESERVATION和广泛的再培养

    公开(公告)号:WO1997039104A1

    公开(公告)日:1997-10-23

    申请号:PCT/US1997006223

    申请日:1997-04-15

    CPC classification number: C12N5/0663 A61K2035/124

    Abstract: Disclosed is a cryopreserved preparation of an isolated, homogeneous population of viable human mesenchymal stem cells obtained from periosteum, bone marrow, cord blood, peripheral blood, dermis, muscle, or other known sources of mesenchymal stem cells. After restoration from cryopreservation, the human mesenchymal stem cells can differentiate into cells of connective tissue types, including bone, cartilage, adipose, tendon, ligament, muscle, dermis, and marrow stromal connective tissue which supports the differentiation of hematopoietic stem cells. The cryopreserved preparation of human mesenchymal stem cells binds to antibodies produced from hybridoma cell lines SH2, SH3, and SH4, which have the ATCC accession numbers HB 10743, GB 10744, and HB 10745, respectively.

    Abstract translation: 公开了从骨膜,骨髓,脐带血,外周血,真皮,肌肉或其它已知的间充质干细胞来源获得的分离的,均匀的存活的人类间充质干细胞群的冷冻保存制剂。 从冷冻保存恢复后,人类间充质干细胞可分化成支持造血干细胞分化的结缔组织类型细胞,包括骨,软骨,脂肪,肌腱,韧带,肌肉,真皮和骨髓基质结缔组织。 人类间充质干细胞的冷冻保存制剂与分别具有ATCC 10743,GB 10744和HB 10745的杂交瘤细胞系SH2,SH3和SH4产生的抗体结合。

    SELECTIVE VACUUM GRIPPER
    20.
    发明申请
    SELECTIVE VACUUM GRIPPER 审中-公开
    选择性真空刮板

    公开(公告)号:WO1997037523A2

    公开(公告)日:1997-10-16

    申请号:PCT/US1997004729

    申请日:1997-03-24

    Abstract: An apparatus for forming an integral three-dimensional object from a plurality of individual laminations includes a cutting surface on which each of the laminations is individually deposited. A concentrated energy source cuts each of the plurality of laminations into a shape required for assembly of the laminations into the integral three-dimensional object. A transfer mechanism removes each of the cut laminations from the cutting surface and stacks each of the cut laminations on an assembly surface. The transfer mechanism includes a gripper face having a peripheral portion and a central portion. A mask is positioned on the gripper face. The mask has an apertured central portion corresponding to the cut lamination. A source of suction communicates with the gripper face and a valve mechanism selectively draws a suction on the gripper face peripheral portion, the gripper face central portion, both or neither. An electronic control device is provided for controlling the operation of the cutting surface, the concentrated energy cutter and the transfer mechanism.

    Abstract translation: 用于从多个单独的叠片形成整体的三维物体的装置包括切割表面,每个叠片分别沉积在该切割表面上。 集中的能量源将多个叠片中的每一个切割成将叠片组装到一体的三维物体中所需的形状。 传送机构从切割表面去除每个切割的叠片并将每个切割的叠片堆叠在组装表面上。 传送机构包括具有周边部分和中心部分的夹持器面。 面罩位于夹具面上。 掩模具有对应于切割层压的有孔的中心部分。 抽吸源与夹持器面连通,并且阀机构选择性地在夹持器表面周边部分,夹持器面中心部分两者或两者上抽吸。 提供一种电子控制装置,用于控制切割表面,集中能量切割器和传送机构的操作。

Patent Agency Ranking